Fulvestrant trials for HR+/HER2- Breast Cancer

All Fulvestrant trials · All HR+/HER2- Breast Cancer trials

Phase breakdown

Recruiting trials studying Fulvestrant for HR+/HER2- Breast Cancer

• A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
  NCT07029399 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
  NCT06998407 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
  NCT07558733 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Study of AVZO-021 in Patients With Advanced Solid Tumors
  NCT05867251 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations

Common questions

How many trials study Fulvestrant for HR+/HER2- Breast Cancer?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.